HOME >> MEDICINE >> NEWS
ENBREL (Etanercept) Patient And Physician Support Web Site Launched

Web Site Offers Important Information And Support Programs For People With Rheumatoid Arthritis And For Their Health Care Providers

SEATTLE, April 6, 1999 - In an effort to better educate patients and health care providers about ENBREL (etanercept), a breakthrough treatment for rheumatoid arthritis (RA), Immunex Corporation and Wyeth-Ayerst Pharmaceuticals have launched the ENBREL Web Site: www.enbrel.com. ENBREL is used to treat moderately to severely active rheumatoid arthritis in people who have not adequately responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).

The comprehensive internet site explains how ENBREL works in the body, offers a question and answer section, provides an interactive quiz to help RA sufferers and their doctors determine if ENBREL may be right for them, and highlights several patients' personal experiences with ENBREL. Color photography and animation add to the graphic interest of the site.

Enbrel.com also offers two toll-free numbers to provide support to patients who are considering or are currently taking ENBREL. For questions about insurance coverage, patients can call the Reimbursement Support Line (1-800-282-7704) where they will be connected with an insurance specialist. To answer any noninsurance questions about ENBREL and RA in general, trained telephone counselors are available at 1-888-4ENBREL. A link to the Arthritis Foundation Web Site is also provided.

Approximately 2.1 million Americans suffer from rheumatoid arthritis, an autoimmune disease that can strike at any age and affects three times as many women as men. ENBREL is the first in a class of rheumatoid arthritis drugs known as biologic response modifiers (BRMs), a new approach to RA management and the first breakthrough treatment in many years for people with rheumatoid arthritis.

In medical studies, just over one third of people treated with ENBREL (etanercept) rep
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
6-Apr-1999


Page: 1 2

Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
5. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
8. Patient with drug-resistant form of HIV identified
9. Patient knows best when it comes to ulcerative colitis, U-M study finds
10. Patients with cancer have highly increased risk for blood clots
11. Patients with previous heart attacks may not benefit from pacemaker implant

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... ... SearchLight is the premier online modeling resource for fluorescence microscopists and optical system ... users during last 5 years spanning the globe, SearchLight has become a tremendously ...
(Date:4/27/2017)... DENVER (PRWEB) , ... April 27, 2017 , ... ... the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement to ... enabled by the continuing support of the Jane and Leonard Korman Family Foundation. ...
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... ... 27, 2017 , ... The American Brain Foundation last night ... Neurology Award (PLINA). The couple joins a prestigious list of past PLINA winners, ... actor Michael J. Fox and former U.S. Attorney General Janet Reno. , Smith ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. , the ... MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron Live! assembles ... helping organizations maximize the benefits of mobility in their operations securely. MobileIron ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
Breaking Medicine Technology:
Cached News: